Press Releases UCB

Equities

UCB

BE0003739530

Market Closed - Euronext Bruxelles Other stock markets 16:35:46 03/05/2024 BST			5-day change	1st Jan Change
120.4 ^EUR	-1.15%		-3.29%	+52.66%

04-11	Berenberg Reiterates UCB's Purchase Rating, Raises PT	MT
04-11	UCB : Berenberg, Buy, raises its price target	CF

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

UCB : Acquisition of own shares	04-26	PU
Pioneering innovation, fueling growth: UCB's commitment to delivering differentiated solutions	04-26	PU
UCB : General Meeting of Shareholders 2024	04-25	PU
UCB : receives European Commission approval for BIMZELX▼(bimekizumab) as the first IL-17A and IL-17F biologic for moderate to severe hidradenitis suppurativa	04-22	PU
UCB : FINTEPLA▼ (fenfluramine) oral solution approved in Japan for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS)	04-17	PU
UCB presents new data highlighting developments across expansive neurology portfolio at 76th American Academy of Neurology Annual Meeting	04-15	AQ
UCB : Latest real-world evidence presented at WCO-IOF-ESCEO assesses how EVENITY▼ (romosozumab) can help to close the treatment gap in osteoporosi	04-12	PU
UCB : presents new data highlighting developments across expansive neurology portfolio at 76th American Academy of Neurology (AAN) Annual Meeting	04-12	PU
UCB : Acquisition of own shares - 2024	04-06	PU
UCB : FDA Accepts Supplemental Biologics License Applications for BIMZELX (bimekizumab-bkzx) for Moderate to Severe Hidradenitis Suppurativa and Additional 2mL Device Presentations	04-04	PU
Share Repurchase Program 2024 to cover UCB's Long Term Incentive Plans for employees	04-01	AQ
UCB : Share Repurchase Program 2024 to cover UCB's Long Term Incentive Plans for employees	03-29	PU
UCB : receives positive CHMP opinion for BIMZELX▼(bimekizumab) for the treatment of adults with moderate to severe hidradenitis suppurativa	03-22	PU
UCB Convening Notice to the General Meeting of the Shareholders 2024	03-22	GL
UCB : announces changes on Board of Directors	03-15	PU
UCB : Financial Reporting Document	03-13	PU
UCB : announces strategic investment in IMIDomics, Inc to advance breakthrough solutions for immune-mediated inflammatory diseases	03-04	PU
UCB : Financial Reporting Document	03-04	PU
UCB announces European Commission approval of RYSTIGGO for the treatment of adults with generalized myasthenia gravis in Europe	01-09	AQ
Closing the Knowledge Gap: Including Pregnant and Breastfeeding Individuals in Clinical Trials	12-18	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

UCB : UCB all set to reach new highs

March 08, 2024 at 04:10 pm